Psychedelics field looks ahead after FDA advisers' rejection.
Science (New York, N.Y.) – June 14, 2024
Source: PubMed
Summary
Despite a recent FDA advisory setback for MDMA therapy, the psychedelic medicine field continues advancing. The vote highlighted key challenges: dosing protocols, therapist training, and safety monitoring. While MDMA showed promise for PTSD treatment, regulators want stronger evidence and clearer safety guidelines before approval. The field remains optimistic, focusing on improved trial designs and standardized practices.
Abstract
Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.